Atara Biotherapeutics (ATRA)
(Delayed Data from NSDQ)
$8.27 USD
+0.10 (1.22%)
Updated Aug 6, 2024 04:00 PM ET
After-Market: $8.46 +0.19 (2.30%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth B Momentum B VGM
Brokerage Reports
Atara Biotherapeutics, Inc. [ATRA]
Reports for Purchase
Showing records 101 - 110 ( 110 total )
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
We like the Initial ATA188 Data in Progressive MS. Dose Response Is Key.
Provider: Roth Capital Partners, Inc.
Analyst: CALCAGNINI THOMAS
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provides Update For FDA Filing - Reiterate Buy Rating and $30 PT
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Cell Therapy 2.0: Moving Beyond CAR-Ts in Immuno-Oncology
Provider: Roth Capital Partners, Inc.
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
We are initiating coverage on Atara Biotherapeutics with a Buy rating and $30 PT
Provider: Roth Capital Partners, Inc.